The early antitumor immune response is necessary for tumor growth: Re-visiting prehn's hypothesis in the human melanoma system

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 930-934

  Parmiani, Giorgio ^a   Maccalli, Cristina ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Cancer immunosurveillance; Early tumor growth; Immune escape; Melanoma; Microenvironment; Tumor antigens

Indexed keywords

B RAF KINASE; CXCL13 CHEMOKINE; FC RECEPTOR; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MELAN A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL CYCLE PROGRESSION; DNA REPAIR; DRUG MEGADOSE; GENE MUTATION; HUMAN; INNATE IMMUNITY; MALIGNANT TRANSFORMATION; MELANOMA; NATURAL KILLER CELL; PRIMARY TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ULTRAVIOLET B RADIATION;

EID: 84874699561     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21455     Document Type: Article

References (47)

1. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13:1-27; PMID : 4921480.
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immu-noediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/sci-ence.1203486.
3. Parmiani G, Sensi ML, Castelli C, Rivoltini L, Anichini A. T-cell response to unique and shared antigens and vaccination of cancer patients. Cancer Immun 2002; 2:6; PMID:12747751.
4. Rivoltini L, Canese P, Huber V, Iero M, Pilla L, Valenti R, et al. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther 2005; 5:463-76; PMID:15934826; http://dx.doi.org/10.1517/14712598.5.4.463.
5. Prehn RT. The immune reaction as a stimulator of tumor growth. Science 1972; 176:170-1; PMID:5014438; http://dx.doi.org/10.1126/sci-enc e .176.4031.170
6. Prehn RT. The initial immune reaction to a new tumor antigen is always stimulatory and probably necessary for the tumor's growth. Clin Dev Immunol 2010; 2010:ID851728; PMID:20811480; http://dx.doi.org/10.1155/2010/851728.
7. Outzen HC. Development of ca rcinogen-induced sk in tumors in mice with varied states of immune capacity. Int J Cancer 1980; 26:87-92; PMID:7239715; http://dx.doi.org/10.1002/ijc.2910260114.
8. Willimsky G, Czéh M, Loddenkemper C, Gellermann J, Schmidt K, Wust P, et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 2008; 205:1687-700.; PMID:18573907; http:// dx.doi.org/10.1084/jem.20072016
9. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-47; PMID:16291983; http://dx.doi.org/10.1056/NEJMoa050092.
10. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9:6483-8; PM ID :14 695152 .
11. Sharkey MS, Lizée G, Gonzales MI, Patel S, Topalian SL. CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res 2004; 64:1595-9; PMID:14996715; http://dx.doi.org/10.1158/0008-5472.CAN-03-32 31.
12. Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 2003; 63:2535-45; PMID:12750277.
13. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7:211-7; PMID:15766659; http://dx.doi.org/10.1016/j.ccr.2005.02.013.
14. Stewart T, Henderson R, Grayson H, Opelz G. Reduced incidence of rectal cancer, compared to gastric and colonic cancer, in a population of 73,076 men and women chronically immunosuppressed. Clin Cancer Res 1997; 3:51-5; PMID:9815537.
15. Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB. Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest 2008; 118:3660-70; PMID:18924608; http://dx.doi.org/10.1172/JCI36157.
16. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 2012; 72:2473-80; PMID:22414581; http://dx.doi.org/10.1158/0008-5472.CAN-12-0122.
17. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463:191-6; PMID:20016485; http://dx.doi.org/10.1038/nature08658.
18. Kripke ML. Ultraviolet radiation and immunology: something new under the sun--presidential address. Cancer Res 1994; 54:6102-5; PMID:7954455.
19. Beissert S, Schwarz T. Ultraviolet-induced immu-nosuppression: implications for photocarcino-genesis. Cancer Treat Res 2009; 146:109-21; PMID:19415197; http://dx.doi.org/10.1007/978-0-387-78574-5_10.
20. Zaidi MR, Davis S, Noonan FP, Graff-Cherry C, Hawley TS, Walker RL, et al. Interferon-? links ultraviolet radiation to melanomagenesis in mice. Nature 2011; 469:548-53; PMID:21248750; http://dx.doi.org/10.1038/nature09666.
21. Zorn E, Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 1999; 29:592-601; PMID:10064075; http://dx.doi.org/10.1002/(SICI)1521-4141(199902)29:02<592::AID-IMMU5 92>3.0.CO;2-2.
22. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010; 17:121-34; PMID:20138013; http://dx.doi.org/10.1016/j.ccr.2009.12.019.
23. DeNardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. Cancer Metastasis Rev 2010; 29:309-16; PMID:20405169; http://dx.doi.org/10.1007/s10555-010-9223-6.
24. Hoek KS, Eichhoff OM, Schlegel NC, Döbbeling U, Kobert N, Schaerer L, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008; 68:650-6; PMID:18245463; http://dx.doi.org/10.1158/0008-5472.C A N- 07-2491.
25. Vallacchi V, Daniotti M, Ratti F, Di Stasi D, Deho P, De Filippo A, et al. CCN3/nephroblastoma over-expressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res 2008; 68:715-23; PMID:18245471; http://dx.doi.org/10.1158/0008-5472.CAN-07-2103.
26. Bayer-Garner IB, Hough AJ Jr., Smoller BR. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness. Mod Pathol 1999; 12:770-4; PMID:10463478.
27. Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010; 328:749-52; PMID:20339029; http://dx.doi.org/10.1126/sci-ence.1185837
28. Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115:739-46; PMID:15696196.
29. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al. Suppression of antitu-mor immunity by stromal cells expressing fibroblast activation protein-a. Science 2010; 330:827-30; PMID:21051638; http://dx.doi.org/10.1126/sci-ence.1195300.
30. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A 1998; 95:4510-5; PMID:9539768; http://dx.doi.org/10.1073/pnas.95.8.4510.
31. Loke Y W, King A. Immunology of implantation. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14:827-37; PMID:11023803; http://dx.doi.org/10.1053/beog.2000.0122.
32. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007; 18:460-6; PMID:18023337; http://dx.doi.org/10.1016/j.cop-b i o 2 0 0 7.10 .0 0 7.
33. Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, et al. Immunobiological characterization of cancer stem cells isolated from glio-blastoma patients. Clin Cancer Res 2010; 16:800-13; PMID:20103663; http://dx.doi.org/10.1158/1078-0432.CCR-09-2730.
34. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010; 466:133-7; PMID:20596026; http://dx.doi.org/10.1038/ nature09161.
35. Wei J, Barr J, Kong L-Y, Wang Y, Wu A, Sharma AK, et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 2010 ; 16:461-73; PMID:20068105; http://dx.doi.org/10.1158/1078-0432.CCR-09-1983.
36. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65:9328-37; PMID:16230395; http://dx.doi.org/10.1158/0008-5472.CAN-05-1343.
37. Perego M, Deho P, Tragni G, Carbone A, Della Mina P, Villa A, et al. Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. J Invest Dermatol 2010; 130:1877-86; PMID:20376064; http://dx.doi.org/10.1038/jid.2010.69.
38. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456:593-8; PMID:19052619; http://dx.doi.org/10.1038/nature07567.
39. Held MA, Curley DP, Dankort D, McMahon M, Muthusamy V, Bosenberg MW. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res 2010; 70:388-97; PMID:20048081; http://dx.doi.org/10.1158/0008-5472 .C A N - 09 -2153.
40. Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, Belloni B, et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res 2011; 71:3098-109; PMID:21393506; http://dx.doi.org/10.1158/0008-5472.CAN-10-3997.
41. Schatton T, Schütte U, Frank NY, Zhan Q, Hoerning A, Robles SC, et al. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 2010; 70:697-708; PMID:20068175; http://dx.doi.org/10.1158/0008-5472.CAN-09-1592.
42. Eggermont AMM. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin Cancer Res 2009; 15:6745-7; PMID:19903779; http://dx.doi.org/10.1158/1078-0432.CCR-09-2377.
43. Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an alloge-neic whole-cell melanoma vaccine. Clin Cancer Res 2009; 15:7029-35; PMID:19903777; http://dx.doi.org/10.1158/1078-0432.CCR-09-1540.
44. Slingluff CL Jr., Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, et al. Effect of granulocyte/ macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 2009; 15:7036-44; PMID:19903780; http://dx.doi.org/10.1158/1078-0432.CCR-09-1544 .
45. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007; 18:226-32; PMID:17116643; http://dx.doi.org/10.1093/ annonc/mdl158.
46. Cancervax Corp. Communication, press release, April 2005.
47. Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol 2011; 131:1460-8; PMID:21390049; http://dx.doi.org/10.1038 /jid.2011.58.